Previous Article | Next Article ![]()
Infect Immun, April 1998, p. 1427-1431, Vol. 66, No. 4
Department of Microbiology and Infectious
Diseases, Flinders University of South Australia and Flinders Medical
Centre, Bedford Park, South Australia 5042, Australia,1 and
Laboratory of Bacterial
Pathogenesis and Immunology, The Rockefeller University, New York,
New York 100212
Received 25 September 1997/Returned for modification 30 October
1997/Accepted 8 January 1998
Streptococcus pyogenes evades complement by binding the
complement-regulatory protein factor H (fH) via the central conserved C-repeat region of M protein. However, the corresponding binding region
within fH has not previously been precisely localized. fH is composed
of 20 conserved modules called short consensus repeats (SCRs), each of
which contains approximately 60 amino acids. A series of fH truncated
and deletion mutants were prepared, and their interaction with M6
protein was examined. The M protein binding site was initially
localized to SCRs 6 to 15 as demonstrated by ligand dot blotting,
chemical cross-linking, and enzyme-linked immunosorbent assay. SCR 7 was then shown to contain the M protein binding site, as a construct
consisting of the first seven SCRs bound M protein but a construct
containing the first six SCRs did not bind. In addition, deletion of
SCR 7 from full-length fH abolished binding to M protein. SCR 7 is
known to contain a heparin binding domain, and binding of fH to M6
protein was almost totally inhibited in the presence of 400 U of
heparin per ml. These results localize the M6 protein binding site of
fH to SCR 7 and indicate that it is in close proximity to the heparin
binding site.
The group A Streptococcus
(Streptococcus pyogenes) is one of the most common and
virulent human pathogens. It is responsible for a wide range of
suppurative infections, ranging from skin infections and pharyngitis to
necrotizing fasciitis, bacteremia, and overwhelming infection
(4). Postinfectious sequelae of glomerulonephritis and
rheumatic fever cause widespread morbidity and mortality, especially in
developing countries (33).
Group A streptococci possess a wide variety of virulence factors,
including M protein, hyaluronic acid capsule, serum opacity factor, C5a
peptidase, and extracellular enzymes and toxins (8). M
protein has been intensively studied since Lancefield showed that M
protein-rich strains are resistant to phagocytic killing in nonimmune
human blood (24). M protein appears on electron microscopy
as multiple hairlike projections on the cell surface and consists of
coiled dimers (30, 34). The N terminus of M protein, which
is distal to the bacterial surface, contains a hypervariable region
which defines more than 100 serotypes (19).
Strains of group A streptococci lacking M protein are efficiently
opsonized by the alternative pathway of complement, but in the absence
of type-specific antibody neither the alternative nor the classical
pathway is activated by strains expressing M protein (3,
29). Horstmann et al. demonstrated that M6 protein and other M
serotypes bind factor H (fH), a regulatory protein of the complement
system, resulting in reduced deposition of C3b on the streptococcal
surface (15). The fH binding site on M6 protein has
subsequently been localized to the central conserved C-repeat region
(11).
fH regulates complement activation by acting as a cofactor for factor
I-dependent cleavage of C3b (27) and by disrupting the
alternative pathway C3 convertase (35, 37). fH is a member of the genetically and structurally related regulators of complement activation family of proteins. These proteins all contain similar repetitive structural units of approximately 60 amino acids called short consensus repeats (SCRs) (16). Each SCR contains
approximately 17 conserved amino acids involved in maintaining the
tertiary structure of the module. The ligand binding specificity of
each SCR is thought to reside within the remaining less well-conserved regions (2).
fH is composed of 20 SCR units, each of which is independent of its
neighbor (2). This modularity makes it possible to delete
individual or groups of SCRs without disrupting the overall structure
of the protein. We and others have mapped the SCR domains required for
cofactor activity, decay acceleration, C3b binding, and heparin and
sialic acid binding (6, 13, 22, 23). During the course of
these investigations, Sharma and Pangburn determined that the M protein
binding site in fH is located within SCR 6 to SCR 10 (31).
In this study we confirmed and extended this finding by localizing the
M protein binding site to SCR 7 of fH. Moreover, we demonstrate that
heparin inhibits the binding of fH to M6 protein, indicating that the
two binding sites of fH are closely related in SCR 7.
M6 protein.
M6 protein was purified from the periplasm of
transformed Escherichia coli as previously described
(12). M6 protein was biotinylated by incubating 500 µg of
M6 protein per ml with 1,500 µg of NHS-biotin (Pierce, Rockford,
Ill.) per ml in 50 mM bicarbonate buffer for 30 min at room
temperature. Excess biotin was removed by ultrafiltration in a Microcon
10 microconcentrator (Amicon, Beverly, Mass.).
Cloning and expression of fH mutant proteins.
cDNA encoding
full-length fH (H20), the first seven SCRs of fH (H7), and an SCR 7 deletion of fH (H20
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
M Protein of the Group A Streptococcus
Binds to the Seventh Short Consensus Repeat of Human Complement
Factor H
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
7) were cloned into the mammalian expression
vector BSR
EN as previously described (6, 13).
EN-H5His
was prepared by incorporating into the reverse primer an
EcoRI site, a stop codon, six codons encoding His, and an
XbaI site (reading 5' to 3'). The forward primer was
designed to anneal just 5' to the 18-residue leader sequence and
incorporated an XhoI restriction site. cDNA was amplified by
PCR from a BSR
EN-H20 template by using Vent polymerase (New England
Biolabs, Beverly, Mass.), and was cloned into the XhoI and
EcoRI restriction sites of BSR
EN. This strategy
introduced codons for Ser, Thr, and six His residues into the
construct, and the introduced XbaI site was used to prepare cDNAs encoding other His-tagged proteins without the need for long
reverse primers. BSR
EN-H15His was amplified by PCR in this manner,
using a reverse primer incorporating an XbaI restriction site without a stop codon. Correct identity of the cloned products was
shown by restriction analysis, partial sequencing of the cDNA, and
Western blotting of the expressed protein.
70°C. H20 was
purified by antibody affinity chromatography with anti-fH antibodies
raised in rabbits. After washing of the column, bound protein was
eluted in 3 M glycine acetate (pH 3), dialyzed against 50 mM phosphate
buffer, and concentrated by placing the dialysis tubing in dry
polyethylene glycol flakes (Mr 20,000; Sigma,
St. Louis, Mo.). H5His and H15His were batch purified with
Ni2+-nitrilotriacetic acid-agarose (Qiagen Inc.,
Chatsworth, Calif.). Bound proteins were eluted in 50 mM imidazole
(Sigma), and the buffer was changed to 50 mM phosphate with Microcon
spin concentrators.
Recombinant H7His and H6His were kindly provided by Jens Hellwage,
Bernhard Nocht Institute, Hamburg, Germany. They were prepared in the
pBSV-8His baculovirus expression system as previously described (21).
fH was purified from pooled human serum as previously described
(1).
Binding of fH and mutant proteins to M6 protein. (i) Ligand dot blotting. Five micrograms each of M6 protein and albumin was dried onto a nitrocellulose membrane (Hybond C+; Amersham, Buckinghamshire, United Kingdom) and dried at 37°C for 30 min. Nonspecific binding sites were blocked by incubation with 5% skim milk in 50 mM phosphate buffer for 60 min, and the membrane was then incubated with 0.5 µg of fH or mutant protein per ml for 3 h. Bound protein was then detected by immunoblotting, using polyclonal goat anti-fH antibody (Calbiochem, San Diego, Calif.) and horseradish peroxidase (HRP)-conjugated protein A (Pierce), and finally identified with the ECL chemiluminescence system (Amersham).
(ii) ELISA. For the enzyme-linked immunosorbent assay (ELISA), 0.2 µg of M6 protein or albumin in 100 mM bicarbonate buffer (pH 9.5) was applied overnight to Maxisorb ELISA plates (Nunc, Copenhagen, Denmark). After blocking in 5% skim milk, test proteins were added and incubated for 3 h. After washing with 50 mM phosphate buffer-0.05% Tween 20, bound protein was detected by using polyclonal goat anti-fH antibody and HRP-conjugated protein A as described above. Substrate was added, and the optical density was determined at 490 nm.
The effects of heparin on the M protein-fH interaction were assessed by incubating H7 with immobilized M6 protein in the presence of 0 to 1,600 U of porcine heparin (David Bull Laboratories, Victoria, Australia) per ml. Binding was then assessed by using the same ELISA format as described above.(iii) Chemical cross-linking. Biotinylated M6 protein (0.7 µg) and 1 µg of fH, H15, or H5 were incubated in 50 mM bicarbonate buffer (pH 8.5) in a final volume of 10 µl. After 20 min, dithiobis(succinimidylpropionate) (DSP) (Pierce) was added to 1 mg/ml and incubated for another 30 min at room temperature. The reaction was quenched by the addition of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) nonreducing buffer, and the samples were separated with a 5 to 15% gradient gel. Duplicate reactions without addition of the cross-linker were included. After transfer to nitrocellulose, biotinylated M6 protein was detected with streptavidin-HRP (Vectastain; Vector Laboratories, Burlingame, Calif.) and chemiluminescence (Amersham).
| |
RESULTS |
|---|
|
|
|---|
Expression of fH and fH mutant proteins. Figure 1 shows Western blots of the fH and mutant fH proteins used in these experiments. All proteins migrated on SDS-PAGE as single bands at the expected molecular weights.
|
Binding of fH, H15, and H5 to M protein. Preliminary localization of the M protein binding site of fH was obtained by ligand dot blotting. M6 protein or albumin, immobilized onto nitrocellulose, was incubated with either full-length fH or recombinant truncated proteins containing the first 15 (H15) or first 5 (H5) SCRs. Both fH and H15 bound to immobilized M6 protein, but not to albumin, while no binding of H5 occurred (Fig. 2). These results indicate that the M protein binding site is located somewhere between SCR 6 and SCR 15 inclusive.
|
|
M protein interacts with SCR 7 of fH.
An ELISA test format was
next used to further examine the binding of a series of fH constructs,
including H7 and H6. H7, but neither H6 nor H5, bound to immobilized M6
protein (Fig. 4). No binding of any fH
protein construct to albumin was detected. As expected, fH and H15 also
bound to immobilized M6 protein (data not shown). These results
indicate that SCR 7 is required for M protein binding. In addition,
deletion of SCR 7 from H20 (H20
7) abolished all M6 protein binding
(Fig. 4), confirming the requirement for SCR 7 and indicating that no
other binding site is present in fH. Consistent results were obtained
when His-tagged proteins or proteins expressed in different cell lines
were used: for example, both H7 and H7His bound M6 protein, and H5His
did not (data not shown).
|
Binding of H7 to M protein is inhibited by heparin. We have previously shown that the major heparin and sialic acid binding site of fH is located within SCR 7 (5). We therefore examined the effect of heparin on the H7-M protein interaction. Binding of H7 to M protein was almost totally inhibited by heparin concentrations of greater than 400 U/ml (Fig. 5).
|
| |
DISCUSSION |
|---|
|
|
|---|
Binding of fH is one possible mechanism by which M protein exerts its antiphagocytic effects and contributes to the virulence of group A streptococci. fH binds to the C-repeat domain of M protein (11), but the corresponding M protein binding site on fH has not been precisely localized. The results of this study confirm and extend the results of Sharma and Pangburn (31), who showed that the M protein binding site of fH is located somewhere within SCRs 6 to 10. We have now more precisely localized the M protein binding site to SCR 7 of human fH.
Our initial results showed that fH binds to M protein via a site within
SCRs 6 to 15 (Fig. 2 and 3). After the publication of Sharma and
Pangburn's results (31), we concentrated on SCR domains 6 to 10. By using an ELISA-based method, the M protein binding
characteristics of proteins containing the N-terminal 5, 6, and 7 SCRs
(H5, H6, and H7) were examined. H7 was the only one of these constructs
to bind M protein, indicating the presence of the binding site in SCR
7. Moreover, a recombinant protein consisting of full-length fH from
which SCR 7 had been deleted (H20
7) failed to bind M protein (Fig.
4). This result confirms that SCR 7 contains the M protein binding site
and demonstrates that there are no other binding sites for M protein
within fH. This is in contrast to heparin binding, which has been
localized to two sites: one in SCR 7 (6) and another within
or near SCR 20 (5). Therefore, deletion of SCR 7 from fH
completely abrogates M protein binding yet leaves intact the second
heparin binding site.
As we have previously shown that SCR 7 of fH contains an important heparin and sialic acid binding site (6), the influence of free heparin on the M protein-fH interaction was assessed. Heparin markedly inhibited binding of H7 to immobilized M protein, with almost complete inhibition obtained at concentrations above 400 U/ml (Fig. 5). This result demonstrates that the binding sites for M protein and heparin in SCR 7 are closely related or identical. However, binding of fH to heparin does not appear to be as stringent as the binding of fH to M6 protein: there are two binding sites for heparin (in SCRs 7 and 20), whereas there is just one for M6 protein (in SCR 7). Analysis of the linear amino acid sequences of SCRs 7 and 20 does not immediately identify putative M6 protein or heparin binding sites, but such analysis may be misleading because it does not take into account the complicated tertiary structure of the SCR. The most useful method to further define functional sites within an SCR is likely to be point mutation of individual amino acids. Another potentially useful method would be to analyze the binding of murine and bovine fH to M6 protein. SCR 7 of each has 57% amino acid identity with the human counterpart (32). Preparation and analysis of SCR 1 to 7 constructs of bovine and murine fH would thus assist in localizing binding sites within SCR 7.
fH is thought to play a key role in self- or non-self-recognition by the alternative pathway via its ability to bind to surfaces rich in sialic acid (10, 25). Similarly, in the absence of specific antibody, fH is thought to protect many pathogenic bacteria by binding to their sialic acid capsules (7, 9, 20). The observation that fH binds via SCR 7 to both sialic acid and streptococcal M protein suggests that the specificity of action of fH is mediated by SCR 7, while complement-regulatory activity resides in SCRs 1 to 4 (13, 22, 23). It is noteworthy that a 42-kDa fH-like protein-1 consisting of the N-terminal seven SCRs of fH and 4 additional amino acids exists in serum; this protein may be able to fulfill most of the crucial functions of fH.
Streptococcal M protein contains both a hypervariable and a conserved region. Only antibodies binding to the hypervariable region result in opsonization and phagocytosis (18). The streptococcus is thought to protect its conserved regions from complement by binding fH, thus controlling the amount of C3b deposited. In support of this hypothesis, C3 is deposited irregularly on M-positive streptococci (17), with an associated reduction in phagocytosis (36). M protein has also been reported to bind to a keratinocyte receptor identified as the complement-regulatory protein CD46 (membrane cofactor protein), and this binding has been implicated in streptococcal adherence (26).
After examining an S. pyogenes mutant in which most of the C repeats of the M6 protein were deleted, Perez-Casal et al. (28) concluded that bound fH may not be the only molecule to protect streptococci from phagocytosis, since the organisms were still resistant to killing in nonimmune blood. However, this deletion mutant still contained one half of a C repeat and was still able to bind fH and kerotinocytes, albeit weakly. Consistent with this, Sharma and Pangburn (31) observed that in contrast to an M-negative strain which bound no fH, the C-repeat deletion mutant prepared by Perez-Casal et al. (28) still bound fH but somewhat less than the strain containing an intact M protein molecule. While the pattern of C3b deposition was not examined by Perez-Casal et al., it is possible that there is sufficient binding of fH to the remaining C repeat to protect the mutant from phagocytosis. This is supported by a report of Fischetti et al. (11) showing that the fH binding site on the M protein is located in the spacer between the two repeats removed by Perez-Casal et al. Moreover, a spacer with 50% identity is still present in the mutant prepared by Perez-Casal et al. In addition, Horstmann et al. showed that fH is also able to bind to fibrinogen bound to the B-repeat region of the M molecule (14). Thus, in vivo, the combination of fH binding to both the B and C repeats (although low in the latter) could account for the retained resistance to phagocytosis in the C deletion mutant. The fact that removal of the complete M molecule results in an organism that is easily phagocytosed in normal human blood and does not bind fH supports the notion that M protein alone is the fH binding molecule on streptococci.
Comparison of the antiopsonic effects of fH with those of a mutant of
fH (H20
7) lacking the binding domain to the M protein C repeat
should further define the role of fH binding to other regions of M
protein, particularly to the B-repeat-bound fibrinogen (14).
Therefore, examination of the protective effects of fH, H20
7, and
fH-like protein-1 on different M protein and antiphagocytic capsular
mutants should help to clarify some of the complexities involved in the
pathogenesis of infection by S. pyogenes.
| |
ACKNOWLEDGMENTS |
|---|
This research was supported by an Australian National Health and Medical Research Council Medical Postgraduate Research Scholarship and Project Grant.
We are grateful to Jens Hellwage and Peter Zipfel of the Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany, for providing H6His and H7His.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology and Infectious Diseases, Flinders Medical Centre, Bedford Park, South Australia 5042, Australia. Phone: (61-8)-8204-4720. Fax: (61-8)-8276-8656. E-mail: Tim.Blackmore{at}flinders.edu.au.
Editor: R. E. McCallum
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Avery, V. M., and D. L. Gordon. 1993. Characterization of factor H binding to human polymorphonuclear leukocytes. J. Immunol. 151:5545-5553[Abstract]. |
| 2. | Barlow, P. N., and I. D. Campbell. 1994. Strategy for studying modular proteins: application to complement modules. Methods Enzymol. 239:465-485. |
| 3. |
Bisno, A. L.
1979.
Alternate complement pathway activation by group A streptococci: role of M protein.
Infect. Immun.
26:1172-1176 |
| 4. |
Bisno, A. L., and D. L. Stevens.
1996.
Streptococcal infections of skin and soft tissues.
N. Engl. J. Med.
334:240-245 |
| 5. | Blackmore, T. K., J. Hellwage, P. F. Zipfel, and D. L. Gordon. 1997. Identification of an additional heparin binding domain in the C-terminal region of human factor H. Exp. Clin. Immunogenet. 14:30. |
| 6. | Blackmore, T. K., T. A. Sadlon, H. M. Ward, D. M. Lublin, and D. L. Gordon. 1996. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J. Immunol. 157:5422-5427[Abstract]. |
| 7. |
Brown, E. J.,
K. A. Joiner,
T. A. Gaither,
C. Hammer, and M. M. Frank.
1983.
The interaction of C3b bound to pneumococci with factor H ( 1H globulin), factor I (C3b/C4b inactivator) and properdin factor B of the human complement system.
J. Immunol.
131:409-415[Abstract].
|
| 8. | Curtis, N. 1996. Invasive group A streptococcal infection. Curr. Opin. Infect. Dis. 9:191-202. |
| 9. | Edwards, M. S., D. L. Kasper, H. J. Jennings, C. J. Baker, and A. Nicholson-Weller. 1982. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J. Immunol. 128:1278-1283[Medline]. |
| 10. |
Fearon, D. T.
1978.
Regulation by membrane sialic acid of 1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
Proc. Natl. Acad. Sci. USA
75:1971-1975 |
| 11. | Fischetti, V. A., R. D. Horstmann, and V. Pancholi. 1995. Location of the complement factor H binding site on streptococcal M6 protein. Infect. Immun. 63:149-153[Abstract]. |
| 12. |
Fischetti, V. A.,
K. F. Jones,
B. N. Manjula, and J. R. Scott.
1984.
Streptococcal M protein expressed in Escherichia coli. Localisation, purification, and comparison with streptococcal-derived M protein.
J. Exp. Med.
159:1083-1095 |
| 13. | Gordon, D. L., R. M. Kaufman, T. K. Blackmore, J. Kwong, and D. M. Lublin. 1995. Identification of complement regulatory domains in human factor H. J. Immunol. 155:348-356[Abstract]. |
| 14. |
Horstmann, R. D.,
H. J. Sievertsen,
M. Leippe, and V. A. Fischetti.
1992.
Role of fibrinogen in complement inhibition by streptococcal M protein.
Infect. Immun.
60:5036-5041 |
| 15. |
Horstmann, R. D.,
H. J. Sievertsen,
J. Knochbloch, and V. A. Fischetti.
1988.
Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.
Proc. Natl. Acad. Sci. USA
85:1657-1661 |
| 16. | Hourcade, D., V. M. Holers, and J. P. Atkinson. 1989. The regulators of complement activation (RCA) gene cluster. Adv. Immunol. 45:381-416[Medline]. |
| 17. | Jacks-Weis, J., Y. Kim, and P. P. Cleary. 1982. Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis. J. Immunol. 128:1897-1902[Abstract]. |
| 18. |
Jones, K. F., and V. A. Fischetti.
1988.
The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci.
J. Exp. Med.
167:1114-1123 |
| 19. |
Jones, K. F.,
B. N. Manjula,
K. H. Johnston,
S. K. Hollingshead,
J. R. Scott, and V. A. Fischetti.
1985.
Location of variable and conserved epitopes among the multiple serotypes of M protein.
J. Exp. Med.
161:623-628 |
| 20. |
Kasper, D. L.
1986.
Bacterial capsule old dogma and new tricks.
J. Infect. Dis.
153:407-415[Medline].
|
| 21. | Kühn, S., and P. F. Zipfel. 1995. The baculovirus expression vector pBSV-8His directs secretion of histidine-tagged proteins. Gene 162:225-229[Medline]. |
| 22. | Kühn, S., C. Skerka, and P. F. Zipfel. 1995. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H. J. Immunol. 155:5663-5670[Abstract]. |
| 23. | Kühn, S., and P. F. Zipfel. 1996. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur. J. Immunol. 26:2383-2387[Medline]. |
| 24. | Lancefield, R. C. 1962. Current knowledge of type-specific M antigens of group A streptococci. J. Exp. Med. 89:307-313. |
| 25. |
Meri, S., and M. K. Pangburn.
1990.
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.
Proc. Natl. Acad. Sci. USA
87:3982-3986 |
| 26. |
Okada, N.,
M. K. Liszewski,
J. P. Atkinson, and M. G. Caparon.
1995.
Membrane cofactor protein (CD46) is a keratinocyte receptor for the M protein of the group A streptococcus.
Proc. Natl. Acad. Sci. USA
92:2489-2493 |
| 27. |
Pangburn, M. K.,
R. D. Schreiber, and H. J. Müller-Eberhard.
1977.
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein 1H for cleavage of C3b and C4b in solution.
J. Exp. Med.
146:257-270 |
| 28. | Perez-Casal, J., N. Okada, M. G. Caparon, and J. R. Scott. 1995. Role of the conserved C-repeat region of the M protein of Streptococcus pyogenes. Mol. Microbiol. 15:907-916[Medline]. |
| 29. | Peterson, P. K., D. Schmeling, P. P. Cleary, B. J. Wilkinson, Y. Kim, and P. G. Quie. 1979. Inhibition of alternative complement pathway opsonisation by group A streptococcal M protein. J. Infect. Dis. 139:575-584[Medline]. |
| 30. |
Phillips, G. N.,
P. F. Flicker,
C. Cohen,
B. N. Manjula, and V. A. Fischetti.
1981.
Streptococcal M proteins: alpha-helical coiled-coil structure and arrangement on the cell surface.
Proc. Natl. Acad. Sci. USA
78:4689-4693 |
| 31. | Sharma, A. K., and M. K. Pangburn. 1997. Localization by site-directed mutagenesis of the site in human complement factor H that binds to Streptococcus pyogenes M protein. Infect. Immun. 65:484-487[Abstract]. |
| 32. | Soames, C. J., A. J. Day, and R. B. Sim. 1996. Prediction from sequence comparisons of residues of factor H involved in the interaction with complement component C3b. Biochem. J. 315:523-531. |
| 33. | Stollerman, G. H. 1997. Rheumatic fever. Lancet 349:935-942[Medline]. |
| 34. | Swanson, J., K. C. Hsu, and E. C. Gotschlich. 1969. Electron microscopic studies on streptococci. I. M antigen. J. Exp. Med. 130:1063-1091[Abstract]. |
| 35. |
Weiler, J. M.,
M. R. Daha,
K. F. Austen, and D. T. Fearon.
1976.
Control of the amplification convertase of complement by the plasma protein 1H.
Proc. Natl. Acad. Sci. USA
73:3268-3272 |
| 36. | Weis, J. J., S. K. Law, R. P. Levine, and P. P. Cleary. 1985. Resistance to phagocytosis by group A streptococci: failure of deposited complement opsonins to interact with cellular receptors. J. Immunol. 134:500-505[Abstract]. |
| 37. |
Whaley, K., and S. Ruddy.
1976.
Modulation of the alternative complement pathway by 1H globulin.
J. Exp. Med.
144:1147-1163 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»